{ "run": { "id": "cmnr158dk06dip658jn16y9m0", "region": "US", "assetId": "cmnr158d806dep658h2yha6ra", "ticker": "SYK", "snapshotId": "cmnr158de06dgp658q53h2e0z", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:54.342Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr158de06dgp658q53h2e0z", "assetId": "cmnr158d806dep658h2yha6ra", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 336.29, "price": 340.01, "dayLow": 336.29, "volume": 1730954, "dayHigh": 341.29, "currency": "USD", "prevClose": 332.07, "week52Low": 319.32, "week52High": 404.87 }, "fundamentals": { "pe": 41.3981154299176, "beta": 0.859455915032784, "epsTTM": 8.49, "fcfTTM": 3884000000, "growth": { "epsYoy": 0.08015267175572517, "revenueYoy": 0.1115733569373755 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": 0.1292403248924988, "gross": 0.6396321070234113, "operating": 0.1946567924828794 }, "website": "http://stryker.com", "industry": "Health technology", "pegRatio": 5.16490773458971, "ebitdaTTM": 5562000000, "forwardPe": 23.5727699530516, "marketCap": 144306436547, "totalCash": 4011000000, "totalDebt": 15859000000, "debtEquity": 0.70735950044603, "quickRatio": 1.044264819091609, "revenueTTM": 25116000000, "companyName": "STRYKER CORP", "priceToBook": 5.99160722569135, "currentRatio": 1.893122915062869, "dividendYield": 0.00955841933938012, "returnOnAssets": 0.06784549786807123, "returnOnEquity": 0.144781445138269, "analystOpinions": null, "businessSummary": "Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology (60% of 2024 revenues), which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery (40% of 2024 revenues), which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.", "enterpriseValue": 146179834000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 53000, "sharesOutstanding": 382688675, "enterpriseToEbitda": 26.28188313556275, "analystTargetMedian": null, "enterpriseToRevenue": 5.820187689122472, "operatingCashflowTTM": 5044000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:54.338Z" }, "results": [ { "id": "cmnr158dm06dkp658ui22ziz4", "runId": "cmnr158dk06dip658jn16y9m0", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"SYK\",\"currency\":\"USD\",\"current_price\":340.01,\"target_price_6m\":358,\"target_price_12m\":372,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Leading medtech compounder with durable mid-to-high single-digit organic growth\",\"Mako robotic surgery platform drives share gains in joint replacements\",\"Margin expansion runway from operating leverage and mix shift\",\"Revenue growth of 11.2% YoY demonstrates strong execution across segments\",\"Premium valuation (41x trailing PE) limits upside if growth decelerates\"],\"key_drivers\":[{\"driver\":\"Mako robotic platform installed base expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Procedure volume recovery and aging demographics\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Tuck-in M&A pipeline adding growth vectors\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion toward mid-20s%\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International revenue penetration (currently ~25%)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated net debt ($11.8B) constraining capital flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Premium valuation susceptible to multiple compression\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"PEG ratio of 5.2x signals growth already priced in\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Hospital capital budgets sensitive to macro conditions\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Multiple compression if organic growth decelerates below 7%\",\"Integration risks from acquisition-driven strategy\",\"Tariff or trade policy headwinds on international operations\",\"Rising interest expense on $15.9B debt load\",\"Competitive pressure from Zimmer Biomet, J&J, and Intuitive Surgical\"],\"assumptions\":{\"revenue_cagr_3y\":8.5,\"ebit_margin_target\":23.0,\"wacc\":9.0,\"terminal_multiple\":24.0},\"scenarios\":{\"bear\":{\"target_price\":295,\"prob\":0.20,\"notes\":\"Growth slows to mid-single digits; multiple contracts to ~20x forward EPS.\"},\"base\":{\"target_price\":372,\"prob\":0.55,\"notes\":\"Steady 8-10% revenue growth, margin expansion, ~23-24x forward EPS of ~$15.70.\"},\"bull\":{\"target_price\":425,\"prob\":0.25,\"notes\":\"Accelerating Mako adoption and M&A synergies drive 12%+ growth; re-rates to 26x.\"}},\"method_notes\":\"Forward PE-anchored valuation using ~$15.50-15.70 CY27 EPS estimate (~10% growth on implied forward EPS of ~$14.42). Applied 23-24x multiple reflecting medtech compounder premium but near historical average. 12M return ~9.4% supports BUY. PEG ratio of 5.2x and trailing PE of 41x flag overvaluation risk, partially offset by strong FCF conversion (~$3.9B TTM). Weighted scenario EV = $371. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Multiple compression if organic growth decelerates below 7%", "Integration risks from acquisition-driven strategy", "Tariff or trade policy headwinds on international operations", "Rising interest expense on $15.9B debt load", "Competitive pressure from Zimmer Biomet, J&J, and Intuitive Surgical" ], "ticker": "SYK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady 8-10% revenue growth, margin expansion, ~23-24x forward EPS of ~$15.70.", "target_price": 372 }, "bear": { "prob": 0.2, "notes": "Growth slows to mid-single digits; multiple contracts to ~20x forward EPS.", "target_price": 295 }, "bull": { "prob": 0.25, "notes": "Accelerating Mako adoption and M&A synergies drive 12%+ growth; re-rates to 26x.", "target_price": 425 } }, "confidence": 0.62, "assumptions": { "wacc": 9, "revenue_cagr_3y": 8.5, "terminal_multiple": 24, "ebit_margin_target": 23 }, "key_drivers": [ { "driver": "Mako robotic platform installed base expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Procedure volume recovery and aging demographics", "impact": "HIGH", "direction": "POS" }, { "driver": "Tuck-in M&A pipeline adding growth vectors", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion toward mid-20s%", "impact": "HIGH", "direction": "POS" }, { "driver": "International revenue penetration (currently ~25%)", "impact": "MED", "direction": "POS" }, { "driver": "Elevated net debt ($11.8B) constraining capital flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Premium valuation susceptible to multiple compression", "impact": "HIGH", "direction": "NEG" }, { "driver": "PEG ratio of 5.2x signals growth already priced in", "impact": "MED", "direction": "NEG" }, { "driver": "Hospital capital budgets sensitive to macro conditions", "impact": "MED", "direction": "NEG" } ], "method_notes": "Forward PE-anchored valuation using ~$15.50-15.70 CY27 EPS estimate (~10% growth on implied forward EPS of ~$14.42). Applied 23-24x multiple reflecting medtech compounder premium but near historical average. 12M return ~9.4% supports BUY. PEG ratio of 5.2x and trailing PE of 41x flag overvaluation risk, partially offset by strong FCF conversion (~$3.9B TTM). Weighted scenario EV = $371. Not investment advice.", "current_price": 340.01, "recommendation": "BUY", "thesis_bullets": [ "Leading medtech compounder with durable mid-to-high single-digit organic growth", "Mako robotic surgery platform drives share gains in joint replacements", "Margin expansion runway from operating leverage and mix shift", "Revenue growth of 11.2% YoY demonstrates strong execution across segments", "Premium valuation (41x trailing PE) limits upside if growth decelerates" ], "target_price_6m": 358, "target_price_12m": 372 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35503, "createdAt": "2026-04-09T05:21:54.342Z", "usage": { "inputTokens": 3716, "outputTokens": 1665, "costUsd": 0.060205 } }, { "id": "cmnr158dm06dnp658yfpkyvrt", "runId": "cmnr158dk06dip658jn16y9m0", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"SYK\",\n \"currency\": \"USD\",\n \"current_price\": 340.01,\n \"target_price_6m\": 343.41,\n \"target_price_12m\": 346.81,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Revenue growth driven by medical technology demand.\",\n \"High margins support strong cash flow generation.\",\n \"Elevated valuation multiples limit near-term upside.\",\n \"Moderate EPS growth expected from current levels.\",\n \"Balanced risk-reward with regulatory and competitive risks.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth trajectory\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operating margin stability\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Valuation multiple compression risk\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Debt levels and interest costs\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Industry demand for surgical products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approval processes\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive intensity in medtech\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Innovation and product pipeline\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Regulatory changes impacting device approvals.\",\n \"Economic slowdown reducing elective surgeries.\",\n \"Increased competition from peers.\",\n \"Foreign exchange volatility affecting international sales.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.08,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 320.01, \"prob\": 0.3, \"notes\": \"Lower growth and multiple contraction due to headwinds.\" },\n \"base\": { \"target_price\": 346.81, \"prob\": 0.5, \"notes\": \"Steady execution with moderate revenue and margin growth.\" },\n \"bull\": { \"target_price\": 374.01, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion from innovation.\" }\n },\n \"method_notes\": \"DCF valuation with 8% revenue CAGR, 20% EBIT margin, 8% WACC, terminal multiple 20x. HOLD as expected return ~2%. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI_Equity_Model", "risks": [ "Regulatory changes impacting device approvals.", "Economic slowdown reducing elective surgeries.", "Increased competition from peers.", "Foreign exchange volatility affecting international sales." ], "ticker": "SYK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution with moderate revenue and margin growth.", "target_price": 346.81 }, "bear": { "prob": 0.3, "notes": "Lower growth and multiple contraction due to headwinds.", "target_price": 320.01 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and multiple expansion from innovation.", "target_price": 374.01 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.08, "terminal_multiple": 20, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Revenue growth trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Valuation multiple compression risk", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt levels and interest costs", "impact": "LOW", "direction": "NEG" }, { "driver": "Industry demand for surgical products", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory approval processes", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive intensity in medtech", "impact": "MED", "direction": "NEG" }, { "driver": "Innovation and product pipeline", "impact": "HIGH", "direction": "POS" } ], "method_notes": "DCF valuation with 8% revenue CAGR, 20% EBIT margin, 8% WACC, terminal multiple 20x. HOLD as expected return ~2%. Not investment advice.", "current_price": 340.01, "recommendation": "HOLD", "thesis_bullets": [ "Revenue growth driven by medical technology demand.", "High margins support strong cash flow generation.", "Elevated valuation multiples limit near-term upside.", "Moderate EPS growth expected from current levels.", "Balanced risk-reward with regulatory and competitive risks." ], "target_price_6m": 343.41, "target_price_12m": 346.81 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 357, "createdAt": "2026-04-09T05:21:54.342Z", "usage": { "inputTokens": 2209, "outputTokens": 3811, "costUsd": 0.002219 } }, { "id": "cmnr158dm06dlp6588z21s481", "runId": "cmnr158dk06dip658jn16y9m0", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"SYK\",\n \"currency\": \"USD\",\n \"current_price\": 340.01,\n \"target_price_6m\": 360.00,\n \"target_price_12m\": 385.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Strong elective procedure volumes provide a durable tailwind for orthopedic and MedSurg segments.\",\n \"Mako robotic platform continues to drive market share gains in joint replacement surgeries.\",\n \"Hospital capital expenditure environments remain resilient, supporting large medical equipment purchases.\",\n \"Valuation is reasonable at ~23.5x forward P/E given the double-digit revenue growth profile.\",\n \"Risks include GLP-1 long-term impacts on obesity-driven osteoarthritis and hospital budget constraints.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Elective procedure volumes\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Mako robot placements\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capital budgets\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 drug adoption\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Input cost inflation\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"International market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged hospital staffing shortages limiting surgical procedure capacity.\",\n \"Widespread adoption of GLP-1 weight loss drugs reducing long-term joint replacement TAM.\",\n \"Macroeconomic pressures tightening hospital capital expenditure budgets.\",\n \"Intense competition in surgical robotics from Zimmer Biomet and J&J.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.085,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.075,\n \"terminal_multiple\": 22.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 290.00,\n \"prob\": 0.2,\n \"notes\": \"Hospital capex slows down, GLP-1 fears resurface impacting TAM, and multiple compresses to 20x.\"\n },\n \"base\": {\n \"target_price\": 385.00,\n \"prob\": 0.6,\n \"notes\": \"Steady elective procedure volumes and successful M&A integration drive mid-teens EPS growth.\"\n },\n \"bull\": {\n \"target_price\": 425.00,\n \"prob\": 0.2,\n \"notes\": \"Margin expansion accelerates past 22% operating margin, earning a premium multiple of 28x forward EPS.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (7.5% WACC, 22x terminal P/E) and a 25x forward P/E multiple. Upside of ~13.2% supports a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch-Alpha-v1", "risks": [ "Prolonged hospital staffing shortages limiting surgical procedure capacity.", "Widespread adoption of GLP-1 weight loss drugs reducing long-term joint replacement TAM.", "Macroeconomic pressures tightening hospital capital expenditure budgets.", "Intense competition in surgical robotics from Zimmer Biomet and J&J." ], "ticker": "SYK", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady elective procedure volumes and successful M&A integration drive mid-teens EPS growth.", "target_price": 385 }, "bear": { "prob": 0.2, "notes": "Hospital capex slows down, GLP-1 fears resurface impacting TAM, and multiple compresses to 20x.", "target_price": 290 }, "bull": { "prob": 0.2, "notes": "Margin expansion accelerates past 22% operating margin, earning a premium multiple of 28x forward EPS.", "target_price": 425 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.085, "terminal_multiple": 22, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Elective procedure volumes", "impact": "HIGH", "direction": "POS" }, { "driver": "Mako robot placements", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital capital budgets", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug adoption", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration synergies", "impact": "MED", "direction": "POS" }, { "driver": "Input cost inflation", "impact": "LOW", "direction": "NEG" }, { "driver": "International market expansion", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (7.5% WACC, 22x terminal P/E) and a 25x forward P/E multiple. Upside of ~13.2% supports a BUY rating. Not investment advice.", "current_price": 340.01, "recommendation": "BUY", "thesis_bullets": [ "Strong elective procedure volumes provide a durable tailwind for orthopedic and MedSurg segments.", "Mako robotic platform continues to drive market share gains in joint replacement surgeries.", "Hospital capital expenditure environments remain resilient, supporting large medical equipment purchases.", "Valuation is reasonable at ~23.5x forward P/E given the double-digit revenue growth profile.", "Risks include GLP-1 long-term impacts on obesity-driven osteoarthritis and hospital budget constraints." ], "target_price_6m": 360, "target_price_12m": 385 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24468, "createdAt": "2026-04-09T05:21:54.342Z", "usage": { "inputTokens": 2587, "outputTokens": 904, "costUsd": 0.016022 } }, { "id": "cmnr158dm06djp65817kaodov", "runId": "cmnr158dk06dip658jn16y9m0", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"SYK\",\"currency\":\"USD\",\"current_price\":340.01,\"target_price_6m\":348,\"target_price_12m\":355,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"Procedure volume and implant mix support durable high-single-digit revenue growth.\",\"MedSurg and Neurotechnology breadth offsets orthopedic cyclicality and customer concentration.\",\"Free cash flow and balance sheet support bolt-on M&A and deleveraging.\",\"Hospital budget pressure and elective volatility can slow capital equipment orders.\",\"Premium valuation limits upside unless margins expand faster than expected.\"],\"key_drivers\":[{\"driver\":\"Orthopedic procedure growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Robotics and capital placements\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"MedSurg pricing/mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Bolt-on M&A integration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Hospital capex pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX and international mix\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Multiple compression risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Hospital capex delays reduce equipment placements.\",\"Procedure softness from macro or staffing pressures.\",\"Acquisition integration or recall issues hurt margins.\",\"Rich valuation amplifies downside on guidance misses.\"],\"assumptions\":{\"revenue_cagr_3y\":0.09,\"ebit_margin_target\":0.22,\"wacc\":0.078,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":300,\"prob\":0.2,\"notes\":\"Growth slows and valuation derates as hospitals delay capital purchases.\"},\"base\":{\"target_price\":355,\"prob\":0.55,\"notes\":\"Steady procedure growth and modest margin gains support limited upside.\"},\"bull\":{\"target_price\":405,\"prob\":0.25,\"notes\":\"Robotics, mix, and execution drive faster earnings growth with stable multiples.\"}},\"method_notes\":\"12M TP uses a blended EV/EBIT and FCF-yield framework on snapshot fundamentals, with explicit growth, margin, WACC and multiple assumptions. Rich starting valuation offsets solid execution, leaving ~4% 12M upside and a HOLD. Snapshot quote fields kept authoritative; no sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI o3", "risks": [ "Hospital capex delays reduce equipment placements.", "Procedure softness from macro or staffing pressures.", "Acquisition integration or recall issues hurt margins.", "Rich valuation amplifies downside on guidance misses." ], "ticker": "SYK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady procedure growth and modest margin gains support limited upside.", "target_price": 355 }, "bear": { "prob": 0.2, "notes": "Growth slows and valuation derates as hospitals delay capital purchases.", "target_price": 300 }, "bull": { "prob": 0.25, "notes": "Robotics, mix, and execution drive faster earnings growth with stable multiples.", "target_price": 405 } }, "confidence": 0.64, "assumptions": { "wacc": 0.078, "revenue_cagr_3y": 0.09, "terminal_multiple": 22, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Orthopedic procedure growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Robotics and capital placements", "impact": "MED", "direction": "POS" }, { "driver": "MedSurg pricing/mix", "impact": "MED", "direction": "POS" }, { "driver": "Bolt-on M&A integration", "impact": "MED", "direction": "POS" }, { "driver": "Margin expansion execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital capex pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX and international mix", "impact": "LOW", "direction": "NEG" }, { "driver": "Multiple compression risk", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "12M TP uses a blended EV/EBIT and FCF-yield framework on snapshot fundamentals, with explicit growth, margin, WACC and multiple assumptions. Rich starting valuation offsets solid execution, leaving ~4% 12M upside and a HOLD. Snapshot quote fields kept authoritative; no sell-side targets used; not investment advice.", "current_price": 340.01, "recommendation": "HOLD", "thesis_bullets": [ "Procedure volume and implant mix support durable high-single-digit revenue growth.", "MedSurg and Neurotechnology breadth offsets orthopedic cyclicality and customer concentration.", "Free cash flow and balance sheet support bolt-on M&A and deleveraging.", "Hospital budget pressure and elective volatility can slow capital equipment orders.", "Premium valuation limits upside unless margins expand faster than expected." ], "target_price_6m": 348, "target_price_12m": 355 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_08a7adff3ef3907a0069d75d9bf8c0819694de190863db230b", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 64495, "createdAt": "2026-04-09T05:21:54.342Z", "usage": { "inputTokens": 2481, "outputTokens": 2660, "costUsd": 0.041582 } }, { "id": "cmnr158dm06dmp658tusn5szz", "runId": "cmnr158dk06dip658jn16y9m0", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Stryker DCF Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"SYK\",\n \"currency\": \"USD\",\n \"current_price\": 340.01,\n \"target_price_6m\": 360,\n \"target_price_12m\": 375,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong position in orthopedics and neurotechnology drives growth.\",\n \"Innovation in robotics supports market share gains.\",\n \"Consistent cash flow funds R&D, M&A and dividends.\",\n \"Favorable demographics boost long-term procedure demand.\",\n \"Premium valuation offset by margin expansion potential.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Aging population increasing procedure volumes\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Robotics and innovation leadership\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A synergy and integration success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Margin expansion through efficiencies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital budget and capex volatility\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition in orthopedic implants\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory and reimbursement changes\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"International market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Economic slowdown reducing elective surgeries\",\n \"Supply chain disruptions and cost inflation\",\n \"Intense competition from medtech peers\",\n \"Changes in healthcare reimbursement policies\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.085,\n \"ebit_margin_target\": 0.21,\n \"wacc\": 0.082,\n \"terminal_multiple\": 26\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 300,\n \"prob\": 0.25,\n \"notes\": \"Recession cuts procedure volumes and compresses valuation.\"\n },\n \"base\": {\n \"target_price\": 375,\n \"prob\": 0.5,\n \"notes\": \"Steady innovation, 8.5% growth and margin gains continue.\"\n },\n \"bull\": {\n \"target_price\": 440,\n \"prob\": 0.25,\n \"notes\": \"Accelerated robotics adoption and M&A drive outsized returns.\"\n }\n },\n \"method_notes\": \"DCF using 8.5% revenue CAGR, 21% EBIT margin, 8.2% WACC and 26x terminal EV/EBIT. Base implies 10% upside supporting BUY. Snapshot used as baseline. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "Stryker DCF Valuation Model", "risks": [ "Economic slowdown reducing elective surgeries", "Supply chain disruptions and cost inflation", "Intense competition from medtech peers", "Changes in healthcare reimbursement policies" ], "ticker": "SYK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady innovation, 8.5% growth and margin gains continue.", "target_price": 375 }, "bear": { "prob": 0.25, "notes": "Recession cuts procedure volumes and compresses valuation.", "target_price": 300 }, "bull": { "prob": 0.25, "notes": "Accelerated robotics adoption and M&A drive outsized returns.", "target_price": 440 } }, "confidence": 0.62, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.085, "terminal_multiple": 26, "ebit_margin_target": 0.21 }, "key_drivers": [ { "driver": "Aging population increasing procedure volumes", "impact": "HIGH", "direction": "POS" }, { "driver": "Robotics and innovation leadership", "impact": "HIGH", "direction": "POS" }, { "driver": "M&A synergy and integration success", "impact": "MED", "direction": "POS" }, { "driver": "Margin expansion through efficiencies", "impact": "MED", "direction": "POS" }, { "driver": "Hospital budget and capex volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Competition in orthopedic implants", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory and reimbursement changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "International market expansion", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 8.5% revenue CAGR, 21% EBIT margin, 8.2% WACC and 26x terminal EV/EBIT. Base implies 10% upside supporting BUY. Snapshot used as baseline. Not investment advice.", "current_price": 340.01, "recommendation": "BUY", "thesis_bullets": [ "Strong position in orthopedics and neurotechnology drives growth.", "Innovation in robotics supports market share gains.", "Consistent cash flow funds R&D, M&A and dividends.", "Favorable demographics boost long-term procedure demand.", "Premium valuation offset by margin expansion potential." ], "target_price_6m": 360, "target_price_12m": 375 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "ac1c2377-dbd6-9677-af64-cd63f4092323", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 14701, "createdAt": "2026-04-09T05:21:54.342Z", "usage": { "inputTokens": 2813, "outputTokens": 3183, "costUsd": 0.056184 } } ] } }